1 / 7

Myasthenia Gravis Therapeutics Pipeline 2017, Clinical Trials, Results and Developments

The study analysed that the myasthenia gravis therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development.

psmarket
Download Presentation

Myasthenia Gravis Therapeutics Pipeline 2017, Clinical Trials, Results and Developments

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myasthenia Gravis Therapeutics Pipeline to have Maximum Drugs to be Developed as Biologics

  2. Myasthenia Gravis Therapeutics According to a new research report “Myasthenia Gravis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Myasthenia Gravis currently exhibits a pipeline of 19 drug candidates. Browse Detailed Summary at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

  3. Myasthenia Gravis Therapeutics Myasthenia Gravis Therapeutics Pipeline in 2017 The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

  4. Myasthenia Gravis Therapeutics Strategic Collaboration for the Development of Myasthenia Gravis Therapeutics Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

  5. Myasthenia Gravis Therapeutics Various Drug Candidates are Being Developed as Biologics It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator. Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

  6. Myasthenia Gravis Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

  7. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related